Clinigen acquisition of Quantum Pharma approved
Clinigen's acquisition of AIM peer Quantum Pharma, a manufacturer and supplier of unlicensed medicines and special obtain products, was approved on Tuesday.
Clinigen Group
925.00p
16:39 04/04/22
0.00%
0.00p
Food & Drug Retailers
3,956.27
16:59 26/04/24
1.04%
40.66
FTSE AIM 100
3,637.40
17:14 26/04/24
n/a
n/a
FTSE AIM 50
3,960.47
17:14 26/04/24
n/a
n/a
FTSE AIM All-Share
755.28
17:14 26/04/24
n/a
n/a
Cancellation of trading of the Quantum shares on AIM will take place on 2 November.